Lecanemab, is a monoclonal antibody used for the treatment of Alzheimer’s disease12. Here are some key points about lecanemab:
Mechanism of Action: Lecanemab targets and removes beta-amyloid plaques from the brain, which are associated with Alzheimer’s disease.
Indications: It is approved for patients with early Alzheimer’s disease, including those with mild cognitive impairment or mild dementia who have confirmed elevated beta-amyloid levels.
Administration: Lecanemab is administered as an intravenous infusion every two weeks. Each infusion takes about one hour.
Efficacy: It has been shown to slow the progression of Alzheimer’s disease, allowing patients more time to participate in daily activities and maintain independence.
Side Effects: Common side effects include infusion-related reactions, headache, and swelling in areas of the brain (known as ARIA - Amyloid Related Imaging Abnormalities)12. Serious side effects can include allergic reactions and ARIA.
Lecanemab represents a significant advancement in the treatment of Alzheimer’s disease by addressing the underlying pathology rather than just the symptoms